Press Release: Second Genome : Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration
BRISBANE, Calif., March 2, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for...
Read full article »
Second Genome is a clinical-stage pharmaceutical company that focuses on developing microbiome-based therapeutics for the treatment of chronical diseases and illness.
Read more